Shattuck Labs Past Earnings Performance
Past criteria checks 0/6
Shattuck Labs's earnings have been declining at an average annual rate of -34.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 15.9% per year.
Key information
-34.1%
Earnings growth rate
7.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -15.9% |
| Return on equity | -60.3% |
| Net Margin | -5,268.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?
Jun 28
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Mar 09Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?
Nov 23Shattuck Labs GAAP EPS of -$0.65 misses by $0.06
Aug 11We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Jul 26Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 18Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Feb 25Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?
Nov 23We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth
Aug 24Shattuck Labs names Abhinav Shukla as chief technical officer
Jun 01Shattuck Labs EPS beats by $0.11, beats on revenue
May 10Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
May 07Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?
Mar 08We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely
Jan 12
Shattuck Labs reports Q3 results
Nov 13Revenue & Expenses BreakdownBeta
How Shattuck Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -87 | 19 | 0 |
| 30 Sep 23 | 1 | -95 | 20 | 0 |
| 30 Jun 23 | 1 | -92 | 21 | 0 |
| 31 Mar 23 | 1 | -98 | 21 | 0 |
| 31 Dec 22 | 1 | -102 | 20 | 0 |
| 30 Sep 22 | 30 | -69 | 21 | 0 |
| 30 Jun 22 | 32 | -61 | 19 | 0 |
| 31 Mar 22 | 28 | -58 | 19 | 0 |
| 31 Dec 21 | 30 | -45 | 19 | 0 |
| 30 Sep 21 | 1 | -65 | 18 | 0 |
| 30 Jun 21 | 2 | -59 | 16 | 0 |
| 31 Mar 21 | 9 | -42 | 12 | 0 |
| 31 Dec 20 | 10 | -37 | 9 | 0 |
| 30 Sep 20 | 11 | -32 | 7 | 0 |
| 30 Jun 20 | 11 | -27 | 6 | 0 |
| 31 Mar 20 | 10 | -26 | 6 | 0 |
| 31 Dec 19 | 10 | -24 | 6 | 0 |
| 31 Dec 18 | 22 | -7 | 4 | 0 |
Quality Earnings: STTK is currently unprofitable.
Growing Profit Margin: STTK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STTK is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accelerating Growth: Unable to compare STTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STTK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: STTK has a negative Return on Equity (-60.33%), as it is currently unprofitable.